ストックスクリーナーアプリを入手
2.0058
0.00%
0.0058
前日終値:
$2.00
開ける：
$1.96
24時間の取引高:
58,956
Relative Volume:
0.02
時価総額：
$9.60M
収益：
-
当期純損益:
$-11.66M
株価収益率:
-0.2459
EPS:
-8.156
ネットキャッシュフロー:
$-11.09M
1週間 パフォーマンス:
+14.29%
1か月 パフォーマンス:
+2.04%
6か月 パフォーマンス:
-31.51%
1年 パフォーマンス:
-69.56%
1日の値動き範囲:
$1.96
$2.03
1週間の範囲:
$1.71
$2.08
52週間の値動き範囲:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
名前
Phio Pharmaceuticals Corp
セクター
電話
(508) 767-3861
住所
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
PHIO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
2.00 | 8.20M | 0 | -11.66M | -11.09M | -8.156 |
|
ONC
Beone Medicines Ltd Adr
|
244.13 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.65 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.48 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
488.77 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-08-05 | 開始されました | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp (PHIO) 最新ニュース
Best Value Stocks to Buy for May 28th - The Globe and Mail
New Strong Buy Stocks for May 28th - The Globe and Mail
New Strong Buy Stocks For May 28th - Barchart.com
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Reveals Latest Progress on Revolutionary Cancer-Fighting siRNA Technology at Investor Conference - Stock Titan
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Phio Cancer Treatment Shows Breakthrough Results: 44% Complete Response Rate in Latest Clinical Trial Data - Stock Titan
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio reports positive results in skin cancer trial - Investing.com
Phio reports positive results in skin cancer trial By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - TradingView
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com
Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World
Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN
3 Penny Stocks to Watch Now, 4/10/25 - TipRanks
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN
Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa
This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail
Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga
Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus
PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus
Is Phio’s Surge Sustainable? - timothysykes.com
Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - marketscreener.com
Phio advances skin cancer treatment with successful trial - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile
Breakthrough in Skin Cancer Trial: PH-762 Shows 100% Tumor Clearance as Study Advances - Stock Titan
Phio stock hits 52-week low at $0.99 amid sharp annual decline - Investing.com
Phio Pharmaceuticals’ (PHIO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Phio stock hits 52-week low at $0.99 amid sharp annual decline By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 - Investing.com Australia
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 By Investing.com - Investing.com India
Phio Pharmaceuticals Corp (PHIO) 財務データ
収益
当期純利益
現金流量
EPS
Phio Pharmaceuticals Corp (PHIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
| Bitterman Robert J | President & CEO |
Jun 07 '24 |
Buy |
0.74 |
1,000 |
740 |
20,990 |
| Bitterman Robert J | President & CEO |
Jun 06 '24 |
Buy |
0.75 |
1,000 |
750 |
19,990 |
1.76%
0.89%
大文字化:
|
ボリューム (24 時間):